Additionally, we did not incorporate molecular profiling (e.g., BRAF, EGFR, KRAS, MET, or NTRK), survival status, or tumor stage data into our analysis, so we could not directly evaluate the prognostic impact of the COVID-19 pandemic on different histologic and molecular subtypes of LC in our region. This evidence concerns the gene KRAS and laryngotracheoesophageal cleft.